Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Researchers are actively testing psilocybin (the active part of “magic mushrooms”) as a possible treatment for several mental health problems. Early clinical trials—usually done under medical supervision with therapy before and after the drug session—have found quick improvements in some people with major depression, anxiety linked to serious illness, and other hard-to-treat conditions (but the studies are still small). (15135,15063,15056) Scientists propose several ways psilocybin might help, such as changing how brain networks communicate, boosting the brain’s ability to form new connections, and lowering brain inflammation. However, the exact reasons are not settled. Safety in careful clinical settings looks acceptable so far, but harms may be underreported, and unsupervised use can carry real risks. More and larger trials are needed, and many groups (for example people of color) were not well represented in early studies. (15132,15050,15135,15061,15095,15056)
This review describes a rapid rise in medical research on psychedelic drugs over the past five years. Several later-stage clinical trials have been published, and many different drugs — including psilocybin, MDMA, ketamine, LSD, ayahuasca, and ibogaine — are being tested for conditions such as depression, post‑traumatic stress, addiction, obsessive‑compulsive…
